Quest believes that it can apply its portfolio of oncology product candidates to prolong, amplify and shape anti-tumor immune responses to increase the clinical benefits of its proprietary antibodies for the treatment of cancer. The following modalities are critical to that approach:

Chemo Enhanced Immuno-Therapy - combining antibodies with front-line chemotherapy can potentially further complement and enhance the treatment outcome compared to antibody treatment alone.

SonoLight Technology – is based on a unique non-toxic family of photosensitizing and sonosensitizing, small molecular weight compounds called Hypocrellin, isolated from a parasitic fungus that grows on bamboo trees in China. Quest’s products are expected to offer high selectivity and efficacy with minimal side effects. Quest is also developing these compounds as an adjuvant to cancer immunotherapy.

Combination Therapy – combining antibodies with a booster compound (adjuvant) that improves the immune system’s response – compared to antibody treatment alone - can potentially complement and enhance the therapeutic outcome.

Antibody Monotherapy – uses the body’s immune system to reject cancer through the administration of therapeutic antibodies, which recruit the patient's immune system to destroy tumor cells. These antibodies can also be used as a vehicle to carry cytotoxic agents such as therapeutic radioisotopes.